Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood

Lancet

Volumn 352, Issue 9142, 1998, Pages 1731-1738

  Van Dongen, Jacques J M ^a,j   Seriu, Taku ^b   Panzer Grümayer, E Renate ^c   Biondi, Andrea ^d   Pongers Willemse, Marja J ^a   Corral, Lilly ^d   Stolz, Frank ^c   Schrappe, Martin ^e   Masera, Giuseppe ^d   Kamps, Willem A ^f,g   Gadner, Helmuth ^c   Van Wering, Elisabeth R ^f   Ludwig, Wolf Dieter ^h   Basso, Giuseppe ⁱ   De Bruijn, Marianne A C ^a   Cazzaniga, Giovanni ^d   Hettinger, Klaudia ^c   Van Der Does Van Den Berg, Anna ^f   Hop, Wim C J ^j   Riehm, Hansjörg ^e   Bartram, Claus R ^b   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d UNIVERSITY OF MILAN   (Italy)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f Dutch Childhood Leukaemia Stud Grp   (Netherlands)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

^h HUMBOLDT UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CHILDHOOD; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; STATISTICAL ANALYSIS; T LYMPHOCYTE RECEPTOR GENE;

EID: 0032576355     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04058-6     Document Type: Article

References (34)

1. 1 Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-33.
2. 2 Veerman AJP, Hählen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996; 14: 911-18.
3. 3 Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children. Lancet 1996; 347: 1783-88.
4. 4 Van Dongen JJM, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992; 6S1: 47-59.
5. 5 Bartram CR. Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy. Clin Chim Acta 1993; 217: 75-83.
6. 6 Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416-34.
7. 7 Van Dongen JJM, Szczepański T, de Bruijn MAC, et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther 1996; 2: 121-33.
8. 8 Davis MM, Björkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334: 395-402.
9. 9 Beishuizen A, Hählen K, Hagemeijer A, et al. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia 1991; 5: 657-67.
10. 10 Steenbergen EJ, Verhagen OJHM, Van Leeuwen EF, et al. Distinct ongoing Ig heavy chain rearrangement processes in childhood B-precursor acute lymphoblastic leukemia. Blood 1993; 82: 581-89.
11. 11 Beishuizen A, Verhoeven M-AJ, Van Wering ER, et al. Analysis of immunoglobulin and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by PCR analysis. Blood 1994; 83: 2238-47.
12. 12 Ghali DW, Panzer S, Fischer S, et al. Heterogeneity of the T-cell receptor δ gene indicating subclone formation in acute precursor B-cell leukemias. Blood 1995; 85: 2795-801.
13. 13 Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
14. 14 Cavé H, Guidal C, Rohrlich P, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of δ and γ T-cell receptor genes. Blood 1994; 83: 1892-902.
15. 15 Steenbergen EJ, Verhagen OJ, Van Leeuwen EF, et al. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis of first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 1995; 9: 1726-34.
16. 16 Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995; 86: 1292-95.
17. 17 Nizet Y, Martial P, Vaerman JL, et al. Follow-up of residual disease (MRD) in B-lineage acute leukemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome. Br J Haematol 1991; 79: 205-10.
18. 18 Biondi A, Yokota S, Hansen-Hagge TE, et al. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 1992; 6: 282-88.
19. 19 Ito Y, Wasserman R, Galili N, et al. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J Clin Oncol 1993; 11: 546-53.
20. 20 Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia (in press).
21. 21 San Miguel JF, Parreira A, Wörmann B, Bartram CR, Janossy G, Van Dongen JJM. Investigation of minimal residual disease in acute non-lymphoblastic leukemia: international standardisation and clinical evaluation. In: Baert A-E, Baig SS, Bardoux C, et al, eds. European Union biomedical and health research: the BIOMED-1 programme. Amsterdam: IOS Press, 1995: 372-73.
22. 22 Breit TM, Wolvers-Tettero ILM, Beishuizen A, Verhoeven M-AJ, Van Wering ER, Van Dongen JJM. Southern blot patterns, frequencies and junctional diversity of T-cell receptor δ gene rearrangements in acute lymphoblastic leukemia. Blood 1993; 82: 3063-74.
23. 23 Breit TM, Beishuizen A, Ludwig W-D, et al. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 1993; 7: 2004-11.
24. 24 Beishuizen A, Verhoeven M-AJ, Mol EJ, Van Dongen JJM. Detection of immunoglobulin kappa light-chain gene rearrangement patterns by Southern blot analysis. Leukemia 1994; 8: 2228-36.
25. 25 Van Dongen JJM., Wolvers-Tettero ILM. Analysis of immunoglobulin and T cell receptor genes. Part I: basic and technical aspects. Clin Chim Acta 1991; 198: 1-91.
26. 26 Beishuizen A, De Bruijn MAC, Pongers-Willemse MJ, et al. Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B-cell leukemias: a new molecular target for detection of minimal residual disease. Leukemia 1997; 11: 2200-07.
27. 27 Seriu T, Hansen-Hagge TE, Erz DHR, Bartram CR. Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clonospecific T cell receptor junctions. Leukemia 1995; 9: 316-20.
28. 28 Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997; 336: 317-23.
29. 29 Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-54.
30. 30 Stiller CA, Bunch KJ. Trends in survival for childhood cancer in Britain diagnosed 1971-85. Br J Cancer 1990; 62: 806-15.
31. 31 Van Dongen-Melman JEWM. Information booklet for parents of children surviving cancer. Leukemia 1997; 11: 1799-806.
32. 32 Van Dongen JJM, Hooijkaas H, Adriaansen HJ, Hählen K, Van Zanen GE. Detection of minimal residual acute lymphoblastic leukemia by immunological marker analysis: possibilities and limitations. In: Hagenbeek A, Löwenberg B, eds. Minimal residual disease in acute leukemia 1986. Dordrecht: M Nijhoff Publishers, 1986: 113-33.
33. 33 Adriaansen HJ, Jacobs BC, Kappers-Klunne MC, Hählen K, Hooijkaas H, Van Dongen JJM. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia 1993; 7: 472-81.
34. 34 Brisco MJ, Sykes PJ, Hughes E, et al. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukemia. Br J Haematol 1997; 99: 314-19.